Announcement PDF ASX/Media Release 26/03/2020 Highlights - COVID-19 market update Minimal impact on Emerald Clinics business as patient numbers to date remain strong with ~80% of recent appointments supported by Telehealth Emerald extending its Real World Evidence (RWE) platform to support the growing need to monitor COVID-19 patients and those self-isolating Emerald Clinics MD & CEO Dr Michael Winlo to present at NWR Virtual Conference today at 1pm AEDT Emerald Clinics Limited (ASX: EMD) (Emerald or the Company), a real world data company developing new insights into the use of medical therapies including cannabinoids, is pleased to provide an update in response to the global COVID-19 pandemic. Emerald’s business has remained stable despite the restrictions being enforced across Australia due to COVID-19, with the patient count continuing to grow and referrals remaining steady. In light of the COVID-19 challenges, the Company has implemented numerous measures to keep both staff and patients safe, while developing and expanding telehealth services. Approximately 80% of recent patient appointments have chosen this option. In addition to simply engaging with a patient over the phone or video conference, the Emerald telehealth service can integrate remote patient health monitoring tools, patient medical records, medication management and other data gathering tools, that provide a much richer and more useful suite of information for the patient and the care giver. Emerald’s Telehealth service is available for all consultations, while still allowing Emerald to gather key real-world data from its patients. The company intends to market its RWE platform to health groups and service providers to assist in managing the COVID-19 pandemic and believes, based on discussions to date, there is a market for its RWE in these circumstances. To date these initial approaches remain incomplete and confidential and the Company notes that there is no guarantee that such approaches will evolve into binding agreements. Emerald's Real World Evidence platform can help support the growing need to monitor patients diagnosed with COVID-19 and those required to self-isolate by improving the understanding of what symptoms and other clinical risk factors are most relevant to assist rapid patient triage patients and help reduce unnecessary strain on the hospital system. The company believes its system can help test and monitor a number of novel therapies and care approaches that are being trialled globally to assist patients in the absence of a vaccine for COVID-19. Emerald Clinics Managing Director and CEO Dr Michael Winlo said: “Our team has been working quickly to extend our RWE platform so we can help address the COVID-19 pandemic for Australian patients and citizens. Emerald has unique resources such as a team of researchfocussed clinicians, a RWE platform and a Telehealth service that can respond to the circumstances. We look forward to exploring this further with several interested parties.” The Company notes however, that the current COVID-19 situation is dynamic and subject to change. The Company continues to monitor the impact of the pandemic on its business and will update the market as and when required. Free virtual conference presentation Dr Winlo will deliver the investor presentation (lodged with ASX on 5th March 2020) to investors, shareholders and other interested parties as part of the NWR Small Cap Virtual Conference at 1pm AEDT today, Thursday 26 March. Event: NWR Communications Virtual Small Cap Conference Time: 1pm AEDT Thursday 26 March Investors can register free online to view the presentation at: https://organizer.runtheworld.today/invitation/670 Investors are invited to submit questions prior to the event to matt@nwrcommunications.com.au. Release authorised by: Dr Michael Winlo, CEO and Managing Director For further information: Dr Michael Winlo CEO (08) 6559 2800 investors@emeraldclinics.com.au Matt Wright Media/investor relations +61 (0) 451 896 420 matt@nwrcommunications.com.au About Emerald Clinics Limited Emerald Clinics Limited (ACN 625 085 734) is an Australian incorporated company that operates a network of specialist medical clinics (Clinics) and uses purpose-built software and technology to gather high quality clinical data from informed and consenting patients to create robust and ethically-sourced evidence. Emerald is a clinical services and healthcare technology company focussed on the provision of care for patients clinically determined to have exhausted conventional therapies and who may be suitable for cannabinoid-based medicines. In addition, Emerald uses technology to capture clinical data that can be used to generate clinical evidence relating to the safety and efficacy of unregistered medicines. Emerald has established four medical centres in Australia in Perth, Sydney, Melbourne and Northern Rivers NSW. Cautionary Note on Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for the Company, the company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a results of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forwardlooking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.